STADA has been 100% owned by BAIN CAPITAL and CINVEN since April 2017.

At what enterprise value was STADA acquired in 2017?

During the acquisition of STADA by BAIN CAPITAL / CINVEN in 2017, the transaction's Enterprise Value is estimated to be in the range of €1–10bn.

What was the EV/EBITDA of STADA when it was acquired by BAIN CAPITAL / CINVEN?

The estimated EV/EBITDA multiple for STADA is in the range of 10x - 18x.

What was the EV/Revenue multiple of STADA when it was acquired by BAIN CAPITAL / CINVEN?

The estimated EV/Revenue multiple for STADA is in the range of 1x - 3x.

When was STADA acquired by BAIN CAPITAL / CINVEN?

STADA was acquired by BAIN CAPITAL / CINVEN in 2017.

What was the revenue of STADA at the time of the deal?

The revenue of STADA at the time of the deal is estimated to be in the range of €1–10bn.

What was the EBITDA of STADA during the acquisition?

STADA's EBITDA is estimated to be in the range of €250–500M.

How is the data for the STADA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the STADA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.stada.com/blog/posts/2017/april/to-the-shareholders-of-stada-arzneimittel-ag-stada-supports-voluntary-public-tender-offer-by-bain-capital-and-cinven#:~:text=The%20offer%20estimates%20STADA's%20equity,we%20have%20jointly%20signed%20today.

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaSTADA

04/2017

STADA acquired by BAIN CAPITAL & CINVEN

GERMANY Life Sciences / Pharma & Biotech / Generics / Labs EV €1–10bn

Context

The Executive Board and Supervisory Board of STADA agreed to support a voluntary public tender offer from Bain Capital and Cinven. The offer of EUR66.00 per share (including dividend) values the company at an Enterprise Value of approximately EUR5.318 billion. This price represents a premium of roughly 49% over the unaffected share price from December 2016. The deal concludes a highly competitive bidding process (where Advent International was also a contender). The strategic rationale is to delist STADA to allow for a more aggressive long-term growth strategy, unburdened by quarterly public reporting.

STADA, which reported an EBITDA margin of [members only] in 2017, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, representing a discount to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Bad Vilbel, Germany, Stada is a leading European pharmaceutical manufacturer. Historically a generics player, the company has successfully transformed into a diversified "three-pillar" business: Consumer Healthcare (brands like Nizoral, Grippostad, Snup), Generics, and Specialty Pharmaceuticals (including Biosimilars).

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2017

2016

Other operations with STADA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2026	STADA	ORIFARM VMS	DENMARK	Nutrition & Dietary Supplements
09/2025	CAPVEST PARTNERS	STADA	GERMANY	Generics / Labs

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
06/2017	CHARTERHOUSE	SERB	BELGIUM	Pharma & Biotech
05/2017	PAI PARTNERS	ELITECH GROUP	FRANCE	Diagnostic Equipment
04/2017	NORDSON CORPORATION	VENTION ADVANCED TECHNOLOGIES	UNITED KINGDOM	Medical Devices
03/2017	ARDIAN	UNITHER	FRANCE	CDMO
02/2017	ECOLAB	LABORATOIRES ANIOS	FRANCE	Medical Consumables
09/2016	ARCHIMED	POLYPLUS	FRANCE	R&D Biotech
09/2016	ARDIAN / IXO PRIVATE EQUITY	LAGARRIGUE	FRANCE	Implants & Prosthetics
06/2016	PAI PARTNERS	ATOS MEDICAL	SWEDEN	Medical Consumables
06/2016	PAI PARTNERS	ETHYPHARM	FRANCE	Pharma & Biotech
06/2016	BRIDGEPOINT / RAISE / FLEXSTONE PARTNERS	ACTEON	FRANCE	Medical Devices

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2026	BAIN CAPITAL	GONG CHA GROUP	TAIWAN	Restaurants / Chains
07/2026	BAIN CAPITAL	Vitabiotics	UNITED KINGDOM	Nutrition & Dietary Supplements
07/2026	BAIN CAPITAL	SupplyOn	GERMANY	Supply Chain & Ops
07/2026	BAIN CAPITAL	Eaton Fiber	UNITED KINGDOM	Infrastructures
06/2026	BAIN CAPITAL	FINETODAY	JAPAN	Hygiene & Beauty Brands
06/2026	BAIN CAPITAL	FDH AERO	UNITED STATES	Industrial & Technical Distribution
06/2026	BAIN CAPITAL	Everllence	GERMANY	Engines & Systems
04/2026	BAIN CAPITAL	Positec Group	CHINA	Home & DIY
03/2026	BAIN CAPITAL	PERPETUAL WEALTH MANAGEMENT	AUSTRALIA	Wealth & Asset Management
03/2026	BAIN CAPITAL	Tingstad	SWEDEN	Hospitality Supplies

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €1–10bn

EBITDA range: €250–500M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of STADA by BAIN CAPITAL / CINVEN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: stada

Acquirer: cinven / bain capital

STADA acquired by BAIN CAPITAL & CINVEN

Context

Target

Multiples

Historical Financials (EUR)

Other operations with STADA

Other operations with STADA

Similar deals in Life Sciences

Other operations with BAIN CAPITAL / CINVEN